This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Galectin Therapeutics CEO Serves On Cancer Immunotherapy Panel At BIO CEO & Investor Conference

Stocks in this article: GALT

NORCROSS, Ga., Feb. 13, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G. Traber, M.D., Chief Executive Officer, President and Chief Medical Officer of Galectin Therapeutics, served on a panel titled "Keeping an I on Oncology: The ASCO Immunotherapy Preview" at the 16 th Annual BIO CEO & Investor Conference. The panel was held February 11, 2014, in New York City.

Immunotherapy, a treatment that uses the body's own immune system to help fight infection and disease, received significant attention over the past year and was named Science magazine's 2013 Breakthrough of the Year. Given the heightened attention, cancer immunotherapy, also known as immuno-oncology, will be a featured topic at the preeminent clinical oncology conference, the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 30-June 3, 2014, at McCormick Place in Chicago, Ill.

Dr. Traber was joined on the panel by several leaders in immunotherapy including Annalisa Jenkins, MBBS, MRCP, Executive VP & Head of Global Research and Development, Merck KGaA; Samuel D. Waksal, PhD, Chairman & CEO, Kadmon Corporation; and Jeffrey S. Weber, MD, PhD, Senior Member, H Lee Moffitt Cancer Center. The panel was moderated by Michael G. King, Jr., Senior Analyst, Biotechnology, JMP Securities.

The panel reviewed the general field of immunotherapy, the recent successes and potential future directions. The launch of Yervoy® (ipilimumab) for the treatment of advanced melanoma and the clinical trial successes of anti-PD1 and anti-PD1-L has generated great interest for the potential of durable clinical responses. However, there is room for improvement as only 10 to 20 percent of patients respond to Yervoy therapy. The panel discussed the many potential targets that are under investigation including positive and negative T-cell agents, tumor vaccines, cellular therapies, adoptive immune therapies and therapies targeting the tumor microenvironment. It was broadly acknowledged that combination therapies will be the ultimate solution for increasing the percentage of responders in various tumor types.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs